Canopy immune-therapeutics is committed to providing an inclusive experience and excellent service to all our customers, including individuals with disabilities.
Currently, our website operates under a legal exemption from full website accessibility requirements in accordance with the Equal Rights for Persons with Disabilities Regulations (Accessibility Adjustments for Service), 2013.
Basis of Exemption: This exemption applies because our company meets the statutory criteria for a small business exemption. Our business turnover falls below the legally defined threshold required for mandatory digital accessibility adjustments.
Alternative Access & Support: Although our website is exempt from standard accessibility adjustments, we still want to ensure you have full access to our services and information. If you experience any difficulty browsing our website, reading our content, or using our services, we are here to help. We provide accessible alternatives via direct communication.
Please reach out to our team, and we will gladly assist you with the information, service, or transaction you need through alternative accessible methods.
Contact Information:
Email: Contact-us@canopy-biotech.com
Last updated: [18/10/2026]
Canopy’s first-in-class Antigen-Drug Conjugates (AgDCs) are designed to redefine treatment of antibody-mediated autoimmune diseases by replacing chronic immunosuppression with targeted immune reprogramming aimed at durable, disease-modifying, symptom-free remission.